Tempus to Present at 44th Annual J.P. Morgan Healthcare Conference

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Key Terms

precision medicine medical

Precision medicine uses a person’s unique genetic makeup, lifestyle and environment to choose treatments and preventive steps that are more likely to work for them than one-size-fits-all approaches. For investors, it matters because it can make therapies more effective and efficient—think tailoring a suit rather than buying off the rack—affecting drug development costs, market size, pricing power and the speed at which therapies win regulatory approval.

01/06/2026 - 08:30 AM

CHICAGO--(BUSINESS WIRE)-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, will participate in the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12-15, 2026, in San Francisco, California.

Tempus Founder and CEO Eric Lefkofsky will deliver a presentation, followed by a live Q&A session, on January 12th, 2026 from 1:30 - 2:10PM PST. The presentation will be available via live webcast here:

https://jpmorgan.metameetings.net/events/healthcare26/sessions/317236-tempus-ai-inc/webcast?gpu_only=true&kiosk=true

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.